RECEIVED **CENTRAL FAX CENTER** 

MAR 1 7 2004

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/019,890

Filing Date:

June 5, 2002

First Named Inventor: Curry

Title:

2-Aminoindane Analogs

Attorney Docket No.:

MBMCO P-1

Examiner:

Zucker

Art Unit:

1621

Via RightFax (Before Final): 703-872-9306 (19 pg. incl. cover)

Commissioner for Patents P.O. Box 1450 Washington, DC 22313-1450

#### **FACSIMILE TRANSMITTAL**

Honorable Sir:

Transmitted herewith is an Election of Species and Amendment for the aboveidentified application.

**CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8(a)** 

I hereby certify that this correspondence is being transmitted to the attention on Paul Zucker of Art Unit 2621 at Facsimile Number 703 872 9806 on March 1702004 in accordance with 37 CFR 1.6(d).

March 17, 2004

Date

Thomas Blankinship

03/24/2004 EEKUBAY1 00000001 100100

10019850

01 FC:2255

1005.00 DA

PAGE 1/19 \* RCVD AT 3/17/2004 5:32:14 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-1/1 \* DNIS:8729306 \* CSID: \* DURATION (mm-ss):02-52

FERENCE

## RECEIVED CENTRAL FAX CENTER

MAR 1 7 2004

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/019,890

Filing Date:

June 5, 2002

First Named Inventor: Curry

Title:

2-Aminoindane Analogs

Attorney Docket No.:

MBMCO P-1

Examiner:

Zucker

Art Unit:

1621


Via RightFax (Before Final): 703-872-9306 (19 pg. incl. cover)

Commissioner for Patents P.O. Box 1450 Washington, DC 22313-1450

## **ELECTION OF SPECIES AND AMENDMENT**

## Honorable Sir:

This is an Election of Species and Amendment for the above-identified application in response to the Office Action mail September 17, 2003. The Applicant hereby respectfully requests an Extension of three (3) months in which to response to the Office Action. The Commissioner is hereby authorized to charge the 3-month extension fee to Deposit Account No. 10-0100 for Lackenbach Siegel, LLP.



## **ELECTION OF SPECIES**

Applicant hereby elects compound 8 as shown on page 38 and claimed in its isomeric forms in dependent claims 4, 7, and 11, namely the top two structures of those claims. Independent claim 1 recites a generic formula (I) that includes compound 8. Independent claim 5 relates to the process for the preparation of a compound of generic formula (I) encompassing the elected compound 8 within its scope. Claims 12 to 17 relate to the intermediates formed in the process of preparing the compound of generic formula (I) as claimed in claim 5.